Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Oncology Institute (TOI) Gross Margin (2021 - 2025)

Oncology Institute's Gross Margin history spans 5 years, with the latest figure at 62.88% for Q4 2025.

  • For Q4 2025, Gross Margin rose 6905.0% year-over-year to 62.88%; the TTM value through Dec 2025 reached 62.67%, up 7.0%, while the annual FY2025 figure was 59.12%, 244.0% down from the prior year.
  • Gross Margin reached 62.88% in Q4 2025 per TOI's latest filing, down from 73.04% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 236.51% in Q4 2021 to a low of 6.17% in Q4 2024.
  • Average Gross Margin over 5 years is 71.37%, with a median of 61.37% recorded in 2024.
  • Peak YoY movement for Gross Margin: crashed -16072bps in 2022, then surged 6905bps in 2025.
  • A 5-year view of Gross Margin shows it stood at 236.51% in 2021, then tumbled by -68bps to 75.79% in 2022, then crashed by -42bps to 43.62% in 2023, then tumbled by -114bps to 6.17% in 2024, then skyrocketed by 1119bps to 62.88% in 2025.
  • Per Business Quant, the three most recent readings for TOI's Gross Margin are 62.88% (Q4 2025), 73.04% (Q3 2025), and 57.36% (Q2 2025).